DISCOUNT OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 09:30:10 06/06/2024 BST | ||
| 4.46 EUR | -1.11% |
|
| 1 month | -1.96% | ||
| 3 months | -0.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 06/06/24 | 4.46 | -1.11% |
| 05/06/24 | 4.51 | -0.66% |
| 04/06/24 | 4.54 | +0.44% |
| 03/06/24 | 4.52 | -0.66% |
| 31/05/24 | 4.55 | +1.56% |
Delayed Quote Deutsche Boerse AG
Last update June 06, 2024 at 09:30 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU1FG0 |
| ISIN | DE000VU1FG05 |
| Date issued | 03/01/2023 |
| Strike | 225 $ |
| Maturity | 21/06/2024 (16 Days) |
| Parity | 10 : 1 |
| Emission price | 2.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.65 € |
|---|---|
| Lowest since issue | 2.68 € |
| Spread | 0.01 € |
| Spread % | 0.22% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
154.8
USD
Average target price
142.8
USD
Spread / Average Target
-7.77%
- Stock Market
- Certificates
- Certificat
